Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease

Jessica R. de Bruyn, Marte A. Becker, Jessica Steenkamer, Manon E. Wildenberg, Sybren L. Meijer, Christianne J. Buskens, Willem A. Bemelman, Mark Löwenberg, Cyriel Y. Ponsioen, Gijs R. van den Brink, Geert R. D'Haens

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis. In a previous trial, patients with ileocecal Crohn's disease were randomized to either immediate ileocecal resection or medical treatment with Infliximab. In case of insufficient response to Infliximab, the latter underwent secondary ileocecal resection. We compared specimens from those patients undergoing immediate resection (Infliximab naïve, n = 20) to those who failed Infliximab therapy (n = 20). Infliximab naïve and Infliximab failure patients had similar severity of inflammation when assessed by CRP levels (median 14 vs 9 mg/L) and histology (Geboes-D'Haens-score, median 10 vs 11 points). On immunohistochemistry, collagen-III and fibronectin depositions were increased in patients previously exposed to Infliximab compared to patients naïve to Infliximab. On mRNA level, procollagen peptidase showed significantly more mucosal mRNA expression in Crohn's disease patients who failed Infliximab. Infliximab responders showed no increase of this marker after 4 weeks of successful Infliximab treatment. Failure to Infliximab therapy is associated with subclinical fibrosis in Crohn's disease
Original languageEnglish
Pages (from-to)e0190999
JournalPLOS ONE
Volume13
Issue number1
DOIs
Publication statusPublished - 2018

Cite this